Evidence map›Paper›PMID 35878742›Full record

ArticleTransplantation and cellular therapy2022

Characterization of Hepatic Dysfunction in Subjects Diagnosed With Chronic GVHD by NIH Consensus Criteria.

Alexander H Yang, Ma Ai Thanda Han, Niharika Samala, Bisharah S Rizvi, Rachel Marchalik, Ohad Etzion, Elizabeth C Wright, Liang Cao, Frances T Hakim, Elizabeth Jones and 9 more

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Transplantation and cellular therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00092235 (Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00092235 recruitingnot on this map

Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease

TypeobservationalSponsorNational Cancer Institute (NCI)Ran2004Enrolled650ConditionsChronic Graft vs. Host Disease
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Alexander H YangNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Liver Diseases Branch, Bethesda, Maryland.
Ma Ai Thanda HanNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Liver Diseases Branch, Bethesda, Maryland.
Niharika SamalaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Liver Diseases Branch, Bethesda, Maryland.
Bisharah S RizviNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Liver Diseases Branch, Bethesda, Maryland.
Rachel MarchalikNational Cancer Institute (NCI), Experimental Transplantation and Immunology Branch, Bethesda, Maryland.
Ohad EtzionNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Liver Diseases Branch, Bethesda, Maryland.
Elizabeth C WrightNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Office of the Director, Bethesda, Maryland.
Liang CaoNational Cancer Institute (NCI), Center for Cancer Research, Genetics Branch, Bethesda, Maryland.
Frances T HakimNational Cancer Institute (NCI), Experimental Transplantation and Immunology Branch, Bethesda, Maryland.
Elizabeth JonesNational Cancer Institute (NCI) Radiology and Imaging Services, Bethesda, Maryland.
Devika KapuriaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Liver Diseases Branch, Bethesda, Maryland.
Dennis D HicksteinNational Cancer Institute (NCI), Immune Deficiency Cellular Therapy Program, Bethesda, Maryland.
Daniel FowlerRapa Therapeutics, Rockville, Maryland.
Jennifer A KanakryNational Cancer Institute (NCI), Experimental Transplantation and Immunology Branch, Bethesda, Maryland.
Christopher G KanakryNational Cancer Institute (NCI), Experimental Transplantation and Immunology Branch, Bethesda, Maryland.
David E KleinerNational Cancer Institute (NCI), Laboratory of Pathology, Bethesda, Maryland.
Christopher KohNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Liver Diseases Branch, Bethesda, Maryland.
Steven Z PavleticNational Cancer Institute (NCI) Radiology and Imaging Services, Bethesda, Maryland.
Theo HellerNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Liver Diseases Branch, Bethesda, Maryland. Electronic address: theoh@intra.niddk.nih.gov.
National Cancer Institute · USNational Institute of Diabetes and Digestive and Kidney Diseases · US

Funding

Deciphering the efficacy of posttransplant cyclophosphamide in haplo transplantZIABC011659 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KANAKRY, CHRISTOPHER · 2015 to 2025
$18.5M
NIH Chronic GVHD Study GroupZIABC011743 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PAVLETIC, STEVEN · 2016 to 2025
$10.2M
Investigation of non-cirrhotic portal hypertension.ZIADK075008 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI HELLER, THEO · 2009 to 2025
$4.5M
Reduced toxicity allogeneic hematopoietic cell transplantation in malignanciesZIABC012065 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KANAKRY, JENNIFER · 2022 to 2025
$3.0M
Intramural NIH HHS ZIA BC011743Intramural NIH HHS ZIA DK075008
6 · The paper itself

Abstract

Hepatic chronic graft-versus-host disease (cGVHD) causes morbidity and current diagnostic criteria are nonspecific. An accurate diagnosis is imperative because overdiagnosis can lead to unnecessary treatment with immunosuppressive agents and raising the risk of opportunistic infections. We aim to characterize different patterns of liver injury and cytokine profiles associated with hepatic dysfunction in cGVHD, to evaluate the accuracy of the NIH Consensus Criteria (NCC) for hepatic cGVHD and to explore predictors for hepatic cGHVD. Patients were evaluated in this prospective cross-sectional study of patients with cGVHD recruited under a natural history protocol. Laboratory tests and cytokines were measured. The cGVHD were diagnosed and scored based on NCC. Clinically indicated liver biopsy specimens or autopsies were reviewed by an expert hepatopathologist (D.E.K.). Comparisons were made between groups, and univariable and multivariable logistic regression were calculated. Of the 302 patients enrolled, 151 fulfilled hepatic cGVHD based on NCC; however, 69% had at least 1 abnormal liver test result. Abnormal alanine aminotransferase (ALT) and aspartate aminotransferase were associated with lower platelets, higher total bilirubin (TB), total cholesterol, serum amyloid A, and IL 15. Abnormal ALP and gamma-glutamyl transpeptidase were associated with higher cholesterol, and IL7. Lower platelet count was associated with higher ALT, TB, and triglycerides and lower albumin. Of the 27 with liver tissue, 16 had histologic features of GVHD, only eight met clinical criteria for hepatic GVHD. Sensitivity and specificity of NCC in identifying hepatic GVHD were 50% and 27% (Kappa = -0.23). Only 6 had only hepatic GVHD, whereas 10 had hepatic GVHD with either iron overload, nodular regenerative hyperplasia, or steatosis. Multivariable logistic regression showed that ALP and total cholesterol were associated with hepatic GVHD and total cholesterol >220 mg/dL increased the sensitivity for histologic hepatic GVHD. In conclusion, abnormal liver enzymes in cGVHD are nonspecific and have poor correlation with histologic evidence for hepatic GVHD, highlighting the importance of histology. Cytokines provide insight into the pathogenesis of hepatic cGVHD. Decreased platelet count was associated with factors associated with liver disease including portal vein diameter, which may suggest progression of liver disease. This highlights the need of incorporating these factors in natural history study and using liver biopsy to understand the development of liver dysfunction in hematopoietic stem cell transplantation and to develop better instruments to decreased hepatic cGVHD related morbidity and mortality. The study was registered with a ClinicalTrials.gov identifier NCT00092235.

Indexed as

Graft vs Host DiseaseLiver DiseasesCholesterolChronic DiseaseConsensusCross-Sectional StudiesCytokinesHumansProspective StudiesCholesterolCytokinesGraft-versus-host diseaseHematopoietic stem cell transplantationLiver dysfunctionMorbidityMortality

Identifiers

PMID35878742
PMCPMC10707451
OpenAlexW4286566349

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.